In the context of non-small cell lung cancer (NSCLC), a recent study demonstrated that Axl expression in the tumor and immune compartments was not associated with overall survival in patients who received first line immunotherapy, but in patients who had received prior chemotherapy, Axl expression was a strong negative prognostic factor (54). Here, AXL is linked to non-small cell lung carcinoma.